User profiles for P. Stockman
 | Paul K StockmanVice President, Oncology Clinical Development, GSK Verified email at GSK.com Cited by 3067 |
Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized …
…, L Zhao, U Scheuring, PK Stockman… - JAMA …, 2020 - jamanetwork.com
Importance Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …
monotherapies or in combination with anti–cytotoxic T-lymphocyte–associated antigen 4 …
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind …
…, M Taboada, M Puglisi, PK Stockman… - The Lancet …, 2017 - thelancet.com
Background New therapeutic strategies for malignant mesothelioma are urgently needed. In
the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated …
the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated …
[HTML][HTML] A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma …
…, NR Smith, P Frewer, J Ratnayake, PK Stockman… - Annals of …, 2017 - Elsevier
Background Approximately 5%–10% of gastric cancers have a fibroblast growth factor
receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase …
receptor-2 (FGFR2) gene amplification. AZD4547 is a selective FGFR-1, 2, 3 tyrosine kinase …
[PDF][PDF] Vandetanib versus gefitinib in patients with advanced non–small-cell lung cancer: results from a two-part, double-blind, randomized phase II study
…, WEE Eberhardt, PK Stockman… - Journal of Clinical …, 2009 - researchgate.net
… In addition to the one-sided P values and 80% CIs specified in the protocol, the two-sided
P values, and corresponding 95% CIs are also reported for completeness. Patients who had …
P values, and corresponding 95% CIs are also reported for completeness. Patients who had …
[HTML][HTML] ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
…, M Powell, R May, U Scheuring, P Stockman… - Annals of …, 2020 - Elsevier
Background Many patients with metastatic non-small-cell lung cancer (mNSCLC) experience
disease progression after first- and second-line treatment; more treatment options are …
disease progression after first- and second-line treatment; more treatment options are …
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
…, S Rigaudeau, P Stockman… - Blood, The Journal …, 2011 - ashpublications.org
… P. Stockman and AG are employees of and own stock in AstraZeneca. GM has an advisory
role with Pfizer and has received honoraria from Novartis and BMS. The remaining authors …
role with Pfizer and has received honoraria from Novartis and BMS. The remaining authors …
Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
…, K Nakagawa, L Zhao, PK Stockman… - Annals of …, 2018 - annalsofoncology.org
Background: Durvalumab (D), a human IgG1 mAb against PD-1 and CD80, has shown clinical
activity in patients (pts) with non-small cell lung cancer (NSCLC). Tremelimumab (T) is a …
activity in patients (pts) with non-small cell lung cancer (NSCLC). Tremelimumab (T) is a …
[HTML][HTML] Clinical evaluation of AZD1152, an iv inhibitor of Aurora B kinase, in patients with solid malignant tumors
…, J Van Der Sar, MP Lolkema, EE Voest, PK Stockman… - Annals of …, 2011 - Elsevier
Background To determine, for each of two dosing schedules, the dose-limiting toxicity (DLT)
and maximum-tolerated dose (MTD) of AZD1152, an Aurora B kinase inhibitor, and to …
and maximum-tolerated dose (MTD) of AZD1152, an Aurora B kinase inhibitor, and to …
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute …
…, K Owen, L Pike, N Schmitt, PK Stockman… - Cancer, 2013 - Wiley Online Library
… , 23.9%; 95% confidence interval, 2.7%-39.9%; P < .05). Although the study was not formally
sized to … Owen, Pike, and Stockman are employees and shareholders of AstraZeneca. …
sized to … Owen, Pike, and Stockman are employees and shareholders of AstraZeneca. …
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics
and safety profile for two different dosing regimens of barasertib, a selective inhibitor …
and safety profile for two different dosing regimens of barasertib, a selective inhibitor …